Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site

29.4.2025 14:00:00 CEST | news aktuell GmbH | Press release

Share

The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.  

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG

Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024.  No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States.

Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's downtown facility. Biomay's headquarters site is a recently constructed, state-of-the-art biomanufacturing facility.

Biomay AG is a privately owned and fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, the expression of recombinant proteins by utilizing E. coli has been Biomay's business focus from the very beginning. Today, Biomay offers cGMP services for manufacturing of therapeutic proteins, plasmid DNA (pDNA) and messenger RNA (mRNA). The company's scope of CDMO services comprises process and analytical development, cell banking, cGMP manufacturing of drug substance and aseptic filling of drug product.

Contact:
Dr. Angela Neubauer, SVP Client Business; E-Mail: request@biomay.com / Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria www.biomay.com

Images

Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site. Credits: Biomay AG
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

NTT DATA Business Solutions Supports SAP Customers in Preparing for the EU Packaging Regulation (PPWR)26.5.2026 12:36:42 CEST | Press release

Bielefeld, Germany — May 26, 2026 —– NTT DATA Business Solutions, a leading SAP Platinum partner for the global SME sector, is strengthening Sustainability Data Simplified, an SAP BTP-based solution, to support customers in meeting the requirements of the EU Packaging and Packaging Waste Regulation (PPWR). The solution builds on long‑standing customer demand for reliable sustainability data and provides a structured foundation for managing regulatory requirements directly within SAP.

The strength of direct sales and a global community / Vorwerk increases 2025 revenue to a record EUR 3.6 billion21.5.2026 13:50:20 CEST | Press release

The Vorwerk Group closed the 2025 financial year with a new record revenue of EUR 3.6 billion despite a challenging market environment. Compared to the previous year, this corresponds to growth of 14.1 percent. The operating result also developed positively at EUR 278 million and was significantly above the previous year’s level (+28.2 percent). At the same time, the financial year marked the first year of implementation of Strategy 2030. The 2025 financial year marked the first year of implementation of Strategy 2030. The success confirms the strategic direction of the Vorwerk Group and once again underlines the strength of the Vorwerk direct sales model and the global Vorwerk community. The akf Bank, the Group’s third-largest business unit with revenue of EUR 673 million, will become even more visible as part of the Group going forward, with a new brand identity and a clear affiliation with Vorwerk.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye